M. T. Krishna, Department of Allergy and Immunology, Birmingham Heartlands Hospital, Bordersley Green East, Birmingham B9 5SS, UK. E-mail: email@example.com
ARTICLES PUBLISHED IN THIS CLINICAL IMMUNOLOGY REVIEW SERIES
Allergy in childhood, allergy diagnosis by use of the clinical immunology laboratory, anaphylaxis, angioedema, desensitization, management of pulmonary disease in primary antibody deficiency, recurrent infections in childhood, recurrent infections in adulthood, recurrent oro-genital ulceration, recurrent superficial abscesses, urticaria, vasculitis/CTD
Allergen immunotherapy describes the treatment of allergic disease through administration of gradually increasing doses of allergen. This form of immune tolerance induction is now safer, more reliably efficacious and better understood than when it was first formally described in 1911. In this paper the authors aim to summarize the current state of the art in immunotherapy in the treatment of inhalant, venom and drug allergies, with specific reference to its practice in the United Kingdom. A practical approach has been taken, with reference to current evidence and guidelines, including illustrative protocols and vaccine schedules. A number of novel approaches and techniques are likely to change considerably the way in which we select and treat allergy patients in the coming decade, and these advances are previewed.
On 10 June 1911, Leonard Noon published the first short description of allergen-specific immunotherapy by injection . His short paper described increasing tolerance to conjunctival challenge testing with grass pollen extract. His work was completed by Freeman , who published a clinical description of improved hay fever symptoms in September of the same year. Between them, these papers described the hypothesis underpinning allergen immunotherapy, the production and standardization of pollen extracts, the use of subcutaneous injections, with short interval up-dosing and longer interval maintenance, and adverse reaction due to overdose. They suggested confirmation of sensitization (by conjunctival challenge) prior to commencing therapy, titration of the starting dose, the choice of the single pollen Phleum pratense from a selection of grass pollen species, and also stated that efficacy is proportional to the duration of prophylactic therapy. At face value it could be argued that these concepts have not changed in the last 100 years. However, the practice of allergen immunotherapy is now supported by a wealth of well-controlled studies, and novel formulations and routes of administration have been investigated. Nonetheless, the gold standard procedure of subcutaneous immunotherapy with P. pratense for hay fever remains alarmingly similar to that described a century ago.
This review of allergen immunotherapy in the treatment of inhalant, venom and drug allergies will focus on patient selection and modalities of administration of this therapy, with specific emphasis on the practicalities of the safe delivery of this service in a specialist centre.
Allergic rhinoconjuctivitis can be treated effectively with immunotherapy, as demonstrated in recent systematic reviews [3–5]. A wide range of aeroallergens, including pollens, house dust mite, animal danders, mould spores and some occupational allergens have been identified as causing allergic airways disease. Standardized allergen extracts are available and the treatment is currently administered either as subcutaneous injection immunotherapy (SCIT) or sublingual immunotherapy (SLIT), and these are discussed in the following sections.
Indications. Careful patient selection is paramount. Clinical benefit can only be expected if the patient's symptoms are truly attributable to an allergic reaction to the implicated allergen. Allergy testing alone cannot confirm this (as the specificity of allergy tests in isolation is low) [6–8] and a detailed clinical history of allergic symptoms consistent with allergen exposure is also required. Challenge testing can be used to confirm specific allergy, but is not often used in routine practice.
Many patients with allergic rhinoconjunctivitis are sensitized to a number of allergens. Evidence does not support the use of mixed allergen preparations, so that only patients with one significant specific allergy (perhaps two) may be considered for immunotherapy using standardized allergen extract. Patients should also be counselled regarding the expected benefits of treatment for them individually in light of their own symptom severity and triggers.
In the United Kingdom, only patients with clinically significant symptoms not controlled adequately with optimal medical therapy are considered for immunotherapy. This means that in practice many patients are treated under close supervision as per British Society for Allergy and Clinical Immunology guidelines , with topical nasal steroids, cromones and antihistamines for a period before enrolment in an immunotherapy programme.
This practice is in contrast to that in other countries, where immunotherapy is often used at an earlier stage, and may even be offered in the hope of modifying disease progression, to prevent the development of new sensitizations and new allergic diseases. A number of recent studies show evidence of such disease modification, but require confirmation in a larger sample size [10–12].
Investigations. Confirmation of sensitization to the specific allergen is a required, but not sufficient, criterion for initiation of immunotherapy. This may be by skin prick testing or detection of serum-specific immunoglobulin (Ig)E. If the patient has mild asthma, verification of adequate control on history and by pulmonary function testing is an important safety consideration.
A guide to evaluation, patient selection and contraindications for allergen-specific immunotherapy in allergic rhinitis is summarized in Table 1.
Table 1. Guide to evaluation and selection of patients for subcutaneous injection immunotherapy/sublingual immunotherapy (SCIT/SLIT) to aero-allergens for allergic rhinitis (#contraindications for specific allergen immunotherapy to aero-allergens).
Evaluate symptoms and response to first-line pharmacotherapy (including compliance, nasal spray technique)
Quality of life significantly affected?
Co-existing local nasal airway pathology such as polyps, deviated septum
Evaluate allergenic trigger from history, e.g. timing of symptoms in the calendar year for hay fever, in case of perennial rhinitis for other factors such as exposure to moulds, animal dander, occupational factors, etc.
Has the patient followed allergen avoidance measures where appropriate?
Consider environmental factors, both indoor as well as outdoor
SCIT protocols. SCIT describes the sequential administration of gradually increasing doses of standardized allergen extract up to a maintenance dose, and then continuation of treatment at this dose for a period of time (usually 3 years). Although target maintenance doses are listed for each product by manufacturers, the dose employed is determined by the patient's clinical tolerance to the vaccine. In other words, a lesser dose is recommended if the patient develops an allergic reaction. Evidence from previous studies has shown that a maintenance dose of 5–20 µg can induce clinical benefit [13–15].
Dosage and regimens. Conventional up-dosing protocols use 12–16 weekly injections during up-dosing, and four to six weekly injections during the maintenance phase. Clustered protocols use two or three injections at each weekly visit, thus reducing the total time required to reach maintenance dose (usually in 7–8 weeks). Rush desensitization protocols have been also described, but are used less often for aeroallergens than for hymenoptera venoms (see below) in view of the higher rate of systemic reactions, including anaphylaxis . Dose reductions are made for delayed or missed injections, during a symptomatic period (for example during the pollen season) or following large local reactions (≥ 10 cm) and systemic reactions.
General health, adverse events, changes in medication and peak expiratory flow are monitored prior to administration of SCIT. An observation period of 1 h after the injection is mandatory, with peak expiratory flow testing prior to discharge. However, severe ‘non-immediate’ reactions can occur up to 24 h after allergen injection.
SLIT. SLIT involves placing the vaccine in solution (drop preparation) or tablet form under the tongue for 1–2 min followed by swallowing. Patient selection for sublingual immunotherapy (SLIT) is identical to that for SCIT. The safety profile of SLIT is superior to SCIT, and serious side effects such as anaphylaxis have been extremely rare [17–23]. Many patients develop minor discomfort in the early phase of treatment, including oropharyngeal pruritis and angioedema, which may require treatment with an antihistamine, but these symptoms usually settle with continued administration of the vaccine.
The indications, contraindications and general considerations in administration of SLIT are the same as described under SCIT. However, there are some special considerations listed as follows.
• One particular preparation (Grazax; ALK Abello, Denmark) currently licensed in the United Kingdom contains fish gelatin. It may be used cautiously in patients with a history of fish allergy, but is absolutely contraindicated in patients with history of anaphylaxis to fish.
• Sublingual vaccines must not be administered if there are raw areas or bleeding in the oral cavity or following dental procedures until the wound is completely healed.
• Where there is an up-dosing schedule, this must be re-started if there has been a gap of ≥ 5 days in vaccine administration.
Dosage and regimens. Sublingual immunotherapy has been used for several aeroallergens including pollens, house dust mite and cat. The optimum dosage, duration and frequency of administration have not yet been established. Sublingual immunotherapy involves a much higher dose of allergen than SCIT. The cumulative monthly dosage of SLIT used in clinical studies has been variable, but has been 0·6–500 times greater than customary SCIT . Several dosing regimens have been employed, including daily (fixed or incremental dosing) [24–26], three times per week  and weekly . With seasonal allergens such as pollen, treatment has been given preseasonally, co-seasonally, pre- and co-seasonally and perennially. Prolonged preseasonal administration induces greater clinical benefit, and if treatment is continued perennially, clinical and immunological responses improve in subsequent years of treatment [29,30]. A recent large placebo-controlled study of sublingual grass pollen tablets showed evidence of persistence of clinical benefit 1 year after stopping treatment , and the results of a further year's follow-up are awaited.
The first dose is given under observation in the clinic and, if tolerated, the patient can then self-administer the treatment daily at home. Clinical follow-up to encourage compliance, monitor for adverse events and to adjust any medical treatment is still recommended.
Efficacy parameters. There are no efficacy parameters or biomarkers that reliably predict or indicate response to treatment . Responses in clinical trials have been assessed using symptom and medication scores and measuring quality of life using a validated questionnaire.
Long-term efficacy has been shown with SCIT to grass pollen. Patients who received treatment for a period of 3 years showed sustained benefit for 7–9 years following discontinuation of desensitization [13,31–34].
Hymenoptera venom immunotherapy (VIT)
VIT is the only specific treatment currently available to reduce the severity and prevent the recurrence of systemic reactions (SR) in patients with a previous history of life-threatening SR or anaphylaxis to hymenoptera insect sting [35–39]. It is highly effective, providing more than 90% protection from reactions to subsequent stings [35,40–42]. Furthermore, it induces a clinically significant improvement in health-related quality of life both in patients with a history of anaphylaxis as well as those with non-life-threatening SRs to hymenoptera stings [43,44]. For a successful clinical outcome in VIT a systematic approach with a good clinical history, and in some cases scrutiny of hospital records relating to previous reactions, are paramount. Knowledge of the insect involved is valuable in making the correct choice of venom. Honey bees usually leave the barbed stinger behind, whereas wasps and hornets usually do not. Details of the circumstances surrounding the sting episode may also provide useful pointers with respect to the nature of the insect.
Indications (Table 2). Anaphylaxis to hymenoptera sting represents a clear indication for VIT [36–38]. However, in patients with non-life-threatening reactions other risk factors such as age, co-morbid conditions, occupation, hobbies, social circumstances and the patient's own choice must be considered carefully prior to making a decision about pursuing VIT. Demonstration of venom-specific IgE is mandatory prior to initiating VIT. Venom immunotherapy is not indicated in patients with local reactions, irrespective of their severity, and further investigations are not warranted [36–38].
Table 2. Indications for venom immunotherapy (VIT).
Large local reaction
Anaphylaxis or grade 4 reaction (Muller grading)
Upper airway or laryngeal oedema and/or severe bronchospasm
Generalized urticaria and/or non-life threatening angioedema or mild bronchospasm
Make a decision after considering occupational risk, hobbies, co-morbid conditions, social circumstances, access to emergency care and patient choice
VIT must not be attempted in patients with history of non-IgE-mediated systemic reactions such as Guillain–Barré syndrome, peripheral neuritis, haematological and renal complications.
Investigations. Skin prick tests (SPT) are the first-line investigation and are carried out at a concentration of 0–100 µg/ml of standardized venom extract . If SPT are negative, intradermal testing (IDT) should be carried out starting at ≤ 0·001 µg/ml and increasing up to a maximum concentration of 1·0 µg/ml . Skin tests have greater sensitivity and specificity than in vitro tests measuring serum venom-specific IgE (SSIgE) . Levels of SSIgE and skin test responses do not correlate with clinical reactivity. Venom-specific IgE can also be measured by a basophil activation test (BAT), but the latter is currently a research tool and does not have significant advantages over routinely employed enzyme immunoassays.
In patients with a history of moderate–severe SR reaction, plasma baseline tryptase should also be measured to screen for underlying disorders of mast cell overload, such as telangectasia macularis eruptiva perstans (TMEP) and other forms of cutaneous (urticaria pigmentosa) and systemic mastocytosis which may warrant further investigation, including bone marrow studies, tissue biopsy and appropriate management [45–50]. Elevated baseline tryptase is an important risk factor for anaphylaxis [45–50] and will have implications for VIT, as discussed in the following sections.
Choice of venom for VIT. This is dictated by clinical history and demonstration of venom-specific IgE. There is no significant cross-reactivity between clinically significant antigens of Apidae and Vespidae (honey bee and wasp/hornet) venoms [51–53]. Within the Vespidae family, there is significant overlap between wasps and hornet venoms [54–56]. However, there is little cross-reactivity between wasps/hornet and paper wasps (not encountered in the United Kingdom) . These facts, as well as knowledge of local entomology of hymenoptera insects, have to be taken into consideration carefully to make a correct choice of the venom for immunotherapy. For example, in a British patient with a history of hornet sting anaphylaxis during a visit to mainland Europe, the ideal choice for immunotherapy would be wasp venom, as the prevalence of wasps is greater in the United Kingdom and wasp venom immunotherapy will protect the patient from either insect sting.
VIT protocols. Different protocols (Example 1), including conventional, clustered, rush and ultra-rush, have been described in the literature. A conventional protocol involves weekly up-dosing, reaching the maintenance dose in 12 weeks [57–60]. Maintenance dose is reached in 4–7 days in a rush up-dosing [61–63] protocol and 1–2 days in an ultra-rush schedule [61,64,65]. A recent national audit in the United Kingdom has shown that more than 90% of allergy specialists employ the conventional protocol, as services in this country are primarily out-patient-based . Accelerated protocols are popular in North America and Europe, and have been shown to be safe as well as efficacious [61,63,64,67–69].
The target maintenance dosage is 100 µg and this is administered at 4-, 6- and 8-weekly intervals during the maintenance phases of years 1, 2 and 3 respectively . Appropriate dose reductions have to be undertaken as with SCIT for aero-allergens in the context of missed injections and large local and systemic reactions. In patients who develop field sting-induced systemic reactions, suggesting treatment failure or inadequate tolerance, escalation of the maintenance dose to 150–200 µg has been shown to be beneficial [37,70].
The safety and efficacy of VIT has not yet been established in patients with elevated plasma baseline tryptase. There are two published reports [46,47] involving a relatively small cohort of patients with urticaria pigmentosa and indolent systemic mastocytosis, showing somewhat conflicting observations and utilizing conventional and clustered up-dosing protocols. It is difficult to make definitive conclusions from these studies, but it is recommended that VIT is carried out cautiously in this group of patients .
Example 1. Protocols for venom immunotherapy (VIT)
Table 3. Example 1.1. Conventional venom immunotherapy (VIT) (as per manufacturer's recommendation – ALK Pharmalgen bee and wasp venom; for a more detailed description refer to the manufacturer's product information).
Dosage in micrograms of bee or wasp venom subcutaneously
Table 4. Example 1.2. Rush venom immunotherapy (VIT) (injections at 60-min intervals each day).
Dosage in micrograms of bee or wasp venom subcutaneously
Table 5. Example 1.3. Ultra-rush venom immunotherapy (VIT) (nine injections over 2 days, day 1: seven injections at 30–60-min intervals; day 2: two injections at 2–4-h intervals; days 1 and 2 as in-patient; maintenance dose of 100 µg given on days 7, 14, 28, 42, 63, 84 and then monthly as out-patient) .
Dosage in micrograms of bee or wasp venom subcutaneously
When to stop VIT. The optimal duration of VIT in UK practice is 3 years. This is seldom prolonged to 5 years or more, but this approach is not evidence-based. It has been recommended that a more prolonged programme of VIT should be considered in patients with history of anaphylactic shock resulting in loss of consciousness, those with history of treatment failure/s (i.e. development of systemic reaction/s or anaphylaxis to field stings while undergoing VIT) or with elevated baseline plasma tryptase (bT) and mastocytosis [36,37,72].
There is little benefit in checking venom-specific IgE at the end of the VIT schedule, as up to 75% of patients continue to demonstrate sensitization . Similarly, while venom-specific IgG4 is induced with VIT, this is not correlated with treatment success [74–77]. Long-term follow-up studies in North America and Europe have shown prolonged efficacy of VIT, with a cumulative risk of 10–15% for the development of SR at 15 years following a treatment period of 3–5 years [73,78].
Practical aspects of SCIT
SCIT must be undertaken only by a specialist with adequate knowledge and experience in this field and in a clinical setting where support for cardiopulmonary resuscitation is readily available. Immunotherapy employing 12-week conventional and 7–8-week cluster protocols can be undertaken in an out-patient facility, but accelerated regimens must be administered in an intensive care or high dependency unit. Protocols for safe delivery of the service (Example 2) must be in place, with particular emphasis on confirmation of identity of the patient, allergen extract and dosage during each visit. A 60-min period of observation is mandatory following each injection in order to monitor the patient closely for development of symptoms of type 1 hypersensitivity reaction. Previous surveys have shown that common causes of allergic reactions during SCIT are misidentification of the patient, administration of the incorrect allergen and dosage errors . Therefore, it is recommended that the injection vial and dosage are checked with another health care professional with experience in SCIT.
Example 2. Safety checks prior to injections in an immunotherapy clinic
1Check patient identity.
2Confirm the allergen involved in treatment.
3Did the patient tolerate the last injection? If not, assess the severity of local and/or systemic reaction/s. Appropriate dose reduction and patient counselling may be necessary.
4In patients premedicated with antihistamine, ensure that they have taken their medication beforehand.
5Enquire for intercurrent infections and any change in medical status since last injection.
6In female patients, enquire about pregnancy.
7In asthmatics, ensure asthma is stable and well controlled.
8Check peak expiratory flow rate (PEFR) at baseline and 60 min following injection or earlier if warranted.
Asthma and SCIT to aeroallergens
Previous reports have also highlighted that near-fatal and fatal anaphylaxis are more common in patients with underlying asthma, and therefore SCIT for aero-allergens is contraindicated in patients with poorly controlled, ‘brittle’ or moderate to severe asthma [38,79]. While mild, well-controlled asthma is not a contraindication for SCIT with aero-allergens, injections must not be administered during intercurrent respiratory infection when there is exaggerated bronchial reactivity, which may predispose patients to the development of a systemic reaction. Poor asthma control is suggested by excessive use of short-acting β2 agonist (more than twice a day), nocturnal symptoms, recurrent courses of oral steroids and hospitalization for acute asthma. A more objective evaluation of asthma control can be obtained by reviewing peak flow charts recorded twice daily for 3–4 weeks with documentation of short-acting β2 agonist usage, as well as baseline spirometry [forced expiratory volume in 1 s (FEV1) should be ≥ 70% predicted].
Asthma and VIT
VIT injections must also not be administered during intercurrent respiratory infection. It is imperative to optimize the anti-inflammatory therapy for asthma prior to commencing VIT and to perform an objective evaluation of asthma as above. VIT is contraindicated in severe or ‘brittle’ asthma, but the approach is somewhat different in moderate asthmatics where a careful ‘risk–benefit’ analysis must be performed for VIT, taking into consideration co-morbid factors, occupation, hobbies and social circumstances as well as patient choice.
Immunotherapy and pregnancy
Allergen immunotherapy in any form must not be initiated during pregnancy . Although allergen immunotherapy is not known to have teratogenic effects, it should ideally be avoided in pregnancy, even in patients established on treatment who are in maintenance phase, in view of the rare but real possibility of anaphylaxis which may cause fetal hypoxia .
Immunotherapy and beta-blocker therapy
Beta-blocker therapy is generally considered an absolute contraindication during allergen-specific immunotherapy due to the risk of refractory anaphylaxis [36–38,80]. This is related to reduced therapeutic efficacy of adrenalin in anaphylaxis due to underlying beta blockade. Therefore, as far as possible, it is better to avoid beta-blockers during immunotherapy, but there are some special circumstances in patients requiring VIT where withdrawal of beta-blockers may put the patient at risk (such as of underlying tachyarrhythmias) [80,81]. In such circumstances, a careful ‘risk–benefit’ analysis must be undertaken, and liaison with the patient's family physician and cardiologist will be beneficial. Where benefit of continuation of treatment of beta-blocker clearly outweigh the risk of their discontinuation, short-acting beta-blockers may be discontinued temporarily prior to injections or during the induction phase of VIT. Some groups have undertaken VIT successfully alongside treatment with beta-blockers. In such circumstances, glucagon must be readily available to treat refractory anaphylaxis .
Immunotherapy and angiotensin-converting enzyme (ACE) inhibitors
ACE inhibitors constitute a relative contraindication for immunotherapy . If possible, these must be replaced with an alternative agent such as angiotensin receptor blocker. While there are some anecdotal reports  in the literature of severe anaphylaxis to VIT in patients on concurrent treatment with ACE inhibitors, a recent retrospective study in a small cohort of patients did not confirm this observation .
Immunotherapy and premedication with antihistamine
There is some evidence in the literature from studies in a small group of subjects that premedication with antihistamine reduces severity of histamine-mediated local reactions, including erythema and induration, and generalized cutaneous response such as urticaria and angioedema, but they do not prevent or abrogate anaphylaxis [65,84,85]. Some allergists express concern about antihistamines potentially masking early symptoms of an allergic reaction to injections, but this is not evidence-based. It is worth noting that recent large multi-centre SCIT hay fever trials included premedication with a short-acting antihistamine .
Allergen standardization and adjuvants
The purpose of allergen standardization is to enhance sensitivity and specificity of the extracts used for diagnosis of allergy as well as to minimize the qualitative and quantitative variation in the composition of the vaccines in order to obtain higher safety standards, efficacy and accuracy. The first international initiative on allergen standardization was the establishment of the Nordic Guidelines, based on Danish Allergen Standardization in 1976 . The World Health Organization (WHO) and European Pharmacopoeia have published guidelines on allergen standardization. In Europe, current guidelines dictate the use of ‘in-house’ reference preparation (IHRP) by all manufacturers for monitoring ‘batch-to-batch’ control [87,88].
The source material for allergy vaccines should represent the allergen to which humans are exposed and should meet the specified criteria for limits on foreign substances and be free of microbial contamination . The manufacturing process must not alter the immunogenicity of the vaccine. A major aspect of allergen standardization is to control for total allergenic potency, which is achieved with international collaboration between manufacturers and control authorities using the same standards that are available from the National Institute of Biological Standards and Control, Herts, UK . The ‘in-house’ reference preparation used by individual laboratories is compared with the international standard and ‘batch-to-batch’ control involves monitoring the quantity of major allergens .
Another approach has been to use chemically modified allergens (allergoids) treated with formaldehyde or glutaraldehyde, which reduce allergenicity (IgE binding) but retain immunogenicity, and so theoretically would reduce the incidence of systemic reactions . These are available for a number of allergens on a named patient basis, including pollens, house dust mite, animal dander and fungal spores.
Aqueous vaccine preparations are employed commonly in the United States, and a mixture of allergens tailored to the patient's sensitization pattern is often used in patients with multiple allergies. In the United Kingdom, in contrast, single allergen preparations are used and are usually alum (aluminium hydroxide) adsorbed [e.g. Alutard vaccines (ALK Abello)]. Alum acts as an adjuvant [down-regulates T helper type 2 (Th2) cell response/s], and slows the release of the allergen into the tissue and circulation, thereby reducing the incidence of SRs [89,90].
Drug desensitization involves a closely supervised graded administration of a drug to a patient with a history of an immediate hypersensitivity response (IgE-mediated and non-IgE-mediated) to that drug. Although there are no controlled clinical trials to validate the dosage regimens employed, there are a number of published case reports/series supporting the efficacy and safety of this process. Drug desensitization has been carried out successfully for a number of IgE-mediated responses, including penicillins, cephalosporins, carbapenems, insulin and platins, as well as for non-IgE-mediated immediate hypersensitivity reactions including aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), radio contrast media and vancomycin [91–102]. In view of the potential risk of anaphylaxis, this procedure must be considered following a careful ‘risk–benefit’ analysis. There are a few clinical scenarios where such a procedure is indicated (Example 3), and it is prudent to establish that desensitization would be life-saving or significantly improve clinical outcome or quality of life in the patient.
Example 3. Indications or common clinical scenarios for drug desensitization
• Life-threatening or serious infections where no alternative antibiotic is available:
○ Syphilis in pregnancy
○ Infective endocarditis
○ Multiple antibiotic allergies in cystic fibrosis
• Non-steroidal anti-inflammatory drugs (NSAIDs): patients requiring pain control as in arthritis and previous history of hypersensitivity reaction to aspirin and/or NSAID
• Protamine hypersensitivity in a patient needing cardiac bypass surgery
In contrast to desensitization with aero-allergens and venoms, where long-term tolerance can be established following a 3–5-year treatment course, tolerance induced by drug desensitization is lost within a few days of stopping the drug . In other words, the process of desensitization has to be repeated each time the patient is exposed to the specific drug after a period of discontinuation. Drug desensitization is principally carried out orally and intravenously, the former being a safer approach. Rapid desensitization protocols have been developed where the therapeutic dosage can be administered within a few hours. Often the starting dose is ≤ 1/1000th the therapeutic dosage, with escalations being carried out in doubling doses at 15–30-min intervals, monitoring the patient closely for symptoms and signs of an allergic reaction. Intravenous desensitization usually involves preparation of three different concentrations of the drug (solutions A, B, C), with a 10-fold increase in concentration between A and C. The rate of infusion of each solution is regulated with a syringe pump in such a way that there are four incremental dosage steps at 15–30-min intervals for each solution.
Rapid drug desensitization must be carried out under the direction and supervision of a specialist in allergy in a high dependency or intensive care unit, where immediate support for resuscitation is available and with a dedicated trained nurse for instituting the desensitization protocol. If the patient develops an allergic reaction, it must be treated promptly with antihistamine, adrenaline and corticosteroids as appropriate to the severity of the response. In such circumstances, dose reduction followed by careful escalation can be re-attempted to establish tolerance. In some patients, this process of dosage reduction followed by escalation may have to be repeated several times in order to achieve the therapeutic dose.
Drug desensitization must not be attempted in non-immediate-type hypersensitivity such as immune complex reactions, acute interstitial nephritis, haemolytic anaemia, toxic epidermal necrolysis and Stevens–Johnson syndrome.
Some relatively common clinical scenarios, including desensitization with penicillin, aspirin and platins, and practical tips are summarized in Examples 3 and 4, respectively.
Example 4. Practical tips for drug desensitization
1Carry out allergy tests where possible and appropriate to demonstrate specific immunoglobulin (Ig)E.
2Perform ‘risk–benefit’ analysis to demonstrate the need for the procedure.
3Counsel patient/relative/guardian and obtain consent.
4Procedure to be performed in a intensive care or high dependency unit where patient can be closely monitored and support for resuscitation is readily available.
5Discontinue beta-blockers as far as possible.
6Involve an experienced pharmacist to prepare the relevant concentrations of the drug.
7It is preferable to have a dedicated nurse to facilitate administration of the drug and provide a written protocol.
8Recognize and treat allergic reactions early and promptly.
Penicillin allergy and desensitization
There are only a few indications for the use of penicillin or related beta lactams in patients with previous history of type 1 hypersensitivity. This applies to infections where no other therapeutically efficacious alternatives are available, and these are summarized in Example 3. Successful oral and intravenous penicillin desensitization protocols have been reported [93,104] (Example 5).
In patients with history of type 1 hypersensitivity to penicillin, aminopenicillins and first- and second-generation cephalosporins must be avoided, but aztreonam, imipenem and third-, fourth- and fifth-generation cephalosporins are usually well tolerated (although these must be administered cautiously) [103,105,106].
Example 5. A protocol+ for oral penicillin desensitization 
Cumulative dose in units
Adapted from Wendel et al. . #This treatment must be delivered in an intensive care or high dependency unit. +Obtain informed consent, check pulse, blood pressure and peak expiratory flow rate and repeat prior to every step. Also, monitor patient for signs and symptoms of allergic reaction.
1 296 700
Parenteral (intravenous) penicillin is given, after which regular doses should be administered for the duration of treatment. Benzathine penicillin (intramuscular) can be given after step 14. Further doses are usually given every 1–3-weekly but a test dose with penicillin V (400 000 U) is given prior to administration of each dose of benzathine penicillin including the first dose after step 14, patient is observed for an hour before administration of benzathine penicillin and further monitoring in hospital overnight is required
Immediate reactions to aspirin and other NSAIDs are not IgE-mediated and several terms have been used to describe these responses, including pseudo-allergy, intolerance, aspirin/NSAID hypersensitivity and idiosyncracy. This is caused by an abnormal shift of arachidonic acid towards the lipoxygenase pathway due to inhibition of cycloxygenase-1, resulting in excessive production of cysteinyl leukotrienes. It was Zeiss and Lockey  who first described a paradoxical observation in 1976 that patients with an intolerance are refractory to aspirin for 3 days following aspirin provocation or challenge. This led to the development of several desensitization protocols.
1Patients with aspirin-exacerbated airways disease (AERD) with moderate–severe asthma with or without associated intractable nasal congestion that is not responding to topical steroids and leukotriene modifiers (antagonists or 5-lipoxygenase inhibitors) should be considered for desensitization.
2Similarly, patients with AERD and moderate–severe asthma requiring recurrent courses of oral corticosteroids may be considered for desensitization.
3Patients with AERD and nasal polyps requiring recurrent surgical resection.
4Patients with AERD or aspirin-induced urticaria, angioedema or anaphylaxis requiring anti-platelet prophylaxis in the context of coronary stent surgery or anti-phospholipid syndrome.
Previous studies have shown that aspirin desensitization improves olfactory function, reduces the need for topical and systemic corticosteroids and reduces infective sinusitis episodes as well as emergency room visits for asthma exacerbations [110,111].
Oral aspirin desensitization protocol is summarized in Example 6. For a more detailed description of preparation of patients for this procedure and treatment of allergic reactions the reader is directed to recently published practice parameter 
Example 6. Oral aspirin desensitization protocol 
• Begin early in the morning and establish intravenous access.
• Administer 20·25 mg aspirin orally followed by 40·5 mg, 81 mg, 162·5 mg and 325 mg at 90-min intervals.
• Review patient's symptoms and check pulse, blood pressure (BP) and forced expiratory volume in 1 s (FEV1) prior to each step of escalation (dose intervals may have to be extended depending on patient's history).
• A decline of FEV1 by ≥ 15% is significant.
• After stabilization of the patient, and at least 3 h after the last dose, provoking dose is repeated. Dose escalation can be continued if well tolerated.
• If decline in FEV1 or symptoms are persistent, i.e. last > 3 h, abandon the process for the day starting on day 2, with previously tolerated dose.
• Usual maintenance dose is 650 mg or 325 mg twice a day. Adapted from Stevenson and Simon .
Desensitization with carboplatin
Carboplatin represents the main drug in the management of ovarian cancer, including treatment of relapses. It is usually well tolerated, but up to 27% of patients treated with seven or more cycles with this agent develop type 1 hypersensitivity with cutaneous manifestations in > 90% of patients, and up to 77% show cardiovascular compromise [112,113]. The non-irritant concentration for skin test is 1–10 mg/ml [114,115]. Rapid desensitization with carboplatin has been carried out successfully (Example 7) in these patients, and this is associated with disappearance of skin test reactivity.
Although several mechanisms have been delineated, in truth no single mechanism is likely to explain all the observed clinical effects and immunological phenomena; this has been described elegantly in recent reviews [116–120].
Noon's paper cited the work of William Dunbar, who showed that antibodies to the pollen ‘toxin’ were found in hay fever patients and could be induced in animals by injection of pollen. He reasoned that inducing pollen ‘anti-toxins’ in hay fever patients would neutralize the effect of the pollen. Today, IgG4 antibodies directed against the allergen are still measured as evidence of a response to immunotherapy. The precise role of the antibodies is controversial; they are proposed to bind to the allergen and prevent its causing mast cell degranulation via IgE binding. Levels of allergen-specific IgG (total IgG or IgG4) do not predict or correlate with a clinical response to immunotherapy [74–77].
Alterations of allergen-induced cytokine production profile have been demonstrated in various studies. While the changes seen vary between studies, the overall trend observed is for a switch from a pro-allergenic Th2 profile, including interleukin (IL)-4 and IL-5 production, towards a Th1 profile characterized by increased interferon (IFN)-γ production [119,121,122]. More recently, the induction of allergen-specific regulatory T cells [CD4+ CD25+ forkhead box P3(Foxp3+)] has been demonstrated, with production of anti-inflammatory cytokines such as IL-10 and transforming growth factor (TGF)-β[123–125].
The overall effect of these changes is to reduce the inflammatory response in the target tissue. This was shown as a marked seasonal reduction in mucosal eosinophil recruitment and an increase in IFN-γ and IL-10 production in nasal mucosal biopsy samples after hay fever immunotherapy .
Many of the mechanisms described for conventional weekly up-dosing regimens of immunotherapy cannot apply to the initial phase of rush desensitization, where tolerance is induced within days. While the changes described above may eventually supervene, the initial rapid induction of tolerance to the allergen is likely to represent tachyphylaxis, where repeated doses of allergen induce a progressively weaker mediator response. Changes in histamine release, cytokine production by T cells and monocytes and even antibody binding activity have been described within the first days of rush immunotherapy. The tolerant state is maintained by continued administration of allergen, and a long-lasting immune tolerance develops as maintenance therapy continues.
What does the future offer?
Allergen immunotherapy is a unique treatment, one of only a few that can truly be said to fundamentally alter a disease state. Therefore, we approach advances in immunotherapy with caution: what can we improve without losing the core benefits? Clearly, we focus on the disadvantages of standard subcutaneous immunotherapy. It is time-consuming both in frequency of treatments and total duration of therapy, it needs to be administered by trained professionals (and is therefore expensive), it requires injections, which are not acceptable to all patients and it is potentially life-threatening. These factors severely restrict the number of individuals who can take advantage of this treatment. If we are to realize the tantalizing prospect of altering the natural history of allergy in a substantial proportion of allergy patients, and even in the population as a whole, then immunotherapy will need to be dramatically different from what is used routinely today.
Modification of allergen
Allergens extracted from their natural source have been in routine use since the inception of SCIT. Standardization of the potency of these biologically variable products represented a major advance and has led to improved safety and efficacy. Various modifications of the allergen have been attempted to increase potency and specificity and to reduce the risk of acute reactions. Allergoid production by formaldehyde treatment of native antigen has long been used, but is associated with reduced efficacy in allergen immunotherapy.
Short peptides, unable to cross-link IgE and induce mast cell degranulation, but able to activate T cells through presentation on human leucocyte antigen (HLA) class II, were shown to induce Th1 reactivity. Initial clinical studies using these short peptides were hampered by significant delayed adverse reactions, probably related to T cell activation. Lower-dose intradermal treatment has been better tolerated and associated with improvement in airway hyper-responsiveness, late-phase skin test response to whole allergen, reduction in nasal symptoms together with up-regulation of CD4+ T cells producing IFN-γ cells but not regulatory T cells following cat peptide immunotherapy [126–130].
It is also possible to induce in-vivo production of allergen by vaccinating with DNA encoding the allergen. While this often produces a Th1-biased response, it is highly dependent on the DNA construct and mode of delivery. Clinical studies of these agents have not progressed . Recombinant allergens offer the hope of better standardization, but their biological efficacy has been uncertain. Recombinant BetV1 protein has also been proven to be as effective as native BetV1 or conventional birch pollen extract in birch pollen SCIT [132,133], and in a recent clinical trial recombinant grass pollen vaccine has also been shown to be clinically safe and effective . Use of recombinant allergens may not only be safer, but may also allow patient-specific vaccines to be produced based on the individual's in vitro IgE reactivity pattern. While current native allergen vaccines modulate the patient's existing allergen-specific IgE, they can also induce new sensitizations to other epitopes of the allergen, previously not present in the patient's serum. The clinical consequences of this, if any, are not known, so any clinical advantage of vaccines based on component-resolved diagnostics remains to be demonstrated.
Enhancement of the allergen with adjuvants itself is not new. Enzyme-potentiated immunotherapy represented an early attempt to increase the potency of the allergen by adding a β-glucuronidase, protamine sulphate and cyclohexanediol. It was not widely adopted, and was shown subsequently to be ineffective .
Another adjuvant, monophosphoryl lipid A (MPL) has been investigated in allergy vaccines. MPL is a purified lipopolysaccharide extracted from the cell walls of Salmonella minnesota[136–138] and induces a Th1 response via Toll-like receptor-4. A large recent multi-centre study with pollen allergoids adsorbed on L-tyrosine formulated with MPL has shown good efficacy and tolerability. Other adjuvants that have been investigated for their strong Th1-evoking ability include immunostimulatory DNA sequences  (ISS) and heat-killed Mycobacterium vaccae. The latter need further investigation in clinical trials.
Many alternative modes of allergen delivery for specific immunotherapy (SIT) aim to induce a T cell response but avoid IgE-binding. Because allergen is presented to T cells in the context of MHC class II, steering allergen towards this pathway is an attractive possibility. Proof of concept and early clinical success has been achieved by fusing recombinant allergen to an intracellular targeting molecule which promotes trafficking into the lysosome, where it is loaded directly onto class II molecules .
Intralymphatic allergen immunotherapy
Intralymphatic injection into subcutaneous lymph nodes (ILIT) is a novel and potentially attractive alternative. Randomized controlled trials in more than 200 patients have shown efficacy in reducing symptoms, and immunomodulatory effects have been seen with doses a tiny fraction of those used in conventional SCIT. In a randomized study in hay fever sufferers, a short protocol of three intralymphatic injections of grass pollen extract over 8 weeks resulted in improvements in symptomatic and laboratory parameters comparable to that achieved with conventional SCIT, even after 3 years . No systemic reactions to ILIT occurred during these studies.
Allergen immunotherapy and anti-IgE monoclonal antibody
Another area of interest is the combination of SCIT with anti-IgE humanized monoclonal antibody. There is some evidence that this approach may induce a synergistic effect with respect to clinical efficacy and enhance safety of accelerated protocols [143,144], but cost of treatment would be the important deterrent.
Allergen-specific immunotherapy is a safe and effective method of treatment for allergic rhinitis and hymenoptera venom allergy, provided this is delivered in a safe and controlled environment with robust patient selection criteria and by a specialist with knowledge and experience in this field. There is emerging evidence that allergen-specific immunotherapy may be indicated early in the course of allergic rhinitis in order to prevent progress of ‘allergic march’ and development of newer sensitizations. It is likely that the future will see better vaccines with reduced allergenicity and greater immunogenicity in order to make them even more safe and efficacious. There may be a role for anti-IgE humanized monoclonal antibody alongside allergen immunotherapy, and studies are under way.
Drug desensitization is gaining popularity, as recent reports have highlighted its success across a range of drugs inducing immediate hypersensitivity responses.
Understanding of the precise mechanisms underlying desensitization will pave the way to development of novel immunomodulatory therapies.
Dr M. T. Krishna is a member of Standards of Care Committee of British Society for Allergy and Clinical Immunology and is the lead author of the guideline ‘Diagnosis and Management of Hymenoptera Venom Allergy’ (submitted for publication).